Century Therapeutics : Corporate Overview November 2023

Corporate Overview

November 2023

Forward-looking statements

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth opportunities are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through

development activities, preclinical studies, and clinical trials; our reliance on the maintenance on certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic, geopolitical issues and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

2

Investment thesis

Next generation platforms for iNK and gamma delta iT candidates

Foundational investments in iPSC technology, genetic editing, and manufacturing

Experienced team in R&D, immuno-oncology, manufacturing and commercialization

Exemplified by FDA clearance of Century's first IND for CNTY-101 & trial execution

Well capitalized with cash runway into 2026

$301.0M in cash, cash equivalents and investments at the end of 2Q23; operational efficiencies designed to enable delivery on key milestones, clinical data

3

iPSC Platform

Building a next generation allogeneic cell therapy platform

iPSC Reprogramming

• Comprehensive collection of clinical grade lines (CD34+ HSC, αβ
  T cell, γδ T cell derived)

iPSC Differentiation/Manufacturing

• Scalable protocols and processes to produce highly functional iNK and iT cell products

Gene Editing

• Proprietary gene editing platform
• • CRISPR MAD7-derived gene editing for precise transgene integration

Protein Engineering

• Developing proprietary next-generation CARs
• Universal tumor targeting platform

Vertically integrated capabilities differentiate Century's approach	5

Foundational investments in iPSC know-how and manufacturing

iPSC license and collaboration agreement established	Established in-house manufacturing accelerates
in 2018	learnings and enables faster product iteration
• Access to clinical grade iPSC lines	• 53,000 ft2 facility
• Exclusive IP and know-how to generate immune effector cells	• Designed to produce multiple immune cell types
using feeder-free methods (NK, T, Mac, DC)	• Two sites provides optionality and maximizes flexibility
• FCDI GMP manufacturing capacity for Century's product
candidates
• Leveraging two decades of research & investment at
University of Wisconsin and FCDI

6

Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells generates uniform product candidates

Sequential selection steps

Multiple gene edits (KO/KI)

iPSC

bank	iSPC Precision Engineering
Engineered iPSC
	Master Cell Bank
	(MCB)

Advantages of Century's Platform

Precise CRISPR mediated homology directed repair reduces

off-target integration

Stepwise and efficient gene editing avoids risky multiplex modification and structural variants

Quality control through generation of homogenous MCB establishes genomic product integrity

Manufacturing begins at the MCB, confirmed to be free from genetic aberrations

CRISPR-mediated HDR (MAD 7)

7

Potential to drive durable responses with engineering to resist immune rejection

Allo-EvasionTM edits + repeat dosing = potential greater durability

With Allo-EvasionTM engineering

Without Allo-EvasionTM engineering

Next-wave of allogeneic cell therapies must solve for challenge of rejection

8

Allo-EvasionTM 1.0 designed to overcome 3 major pathways of host vs graft rejection

CD8+

3 core edits disarm host cells from eliminating therapy

T Cell

1. Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells

2. Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells

β2M KO	HLA-E KI	NK cell	3. Knock-in of HLA-E prevents killing by NK cells

(HLA-I)

CD4+	CIITA KO
T Cell	(HLA-II)

9

Allo-EvasionTM 3.0 provides additional protection against NK cell killing

					4 core edits disarm host cells from eliminating
CD8+					therapy
T Cell					1.	Deletion of β2M, a protein required to express HLA-1 on the
						cell surface prevents recognition by CD8 T cells
					2.	Knock out of CIITA eliminates HLA-II expression to escape
						elimination by CD4 T cells
β2M KO	HLA-E KI	NK cell	3.	Knock-in of HLA-E prevents killing by NK cells
(HLA-I)					4.	Knock-in of HLA-G improves protection against killing by NK
						cells

HLA-G KI

CD4+	CIITA KO
T Cell	(HLA-II)

10